When an ERT is needed for Gaucher disease type 1, choose Cerezyme® (imiglucerase)
Cerezyme is the ONLY ERT (enzyme replacement therapy) that has shown long-term efficacy and safety in multiple studies over 20 years and has been prescribed for over 30 years.1-3
Indication
Cerezyme® (imiglucerase) for injection is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions:
- anemia
- thrombocytopenia
- bone disease
- hepatomegaly or splenomegaly
Cerezyme is the ONLY ERT that demonstrates:
Experience
With over 30 years of real-world experience1,2
- The ERT available for patients with Gaucher disease type 1 worldwide since 19941,2
Efficacy
With multiple studies showing long-term outcomes1,3-5
- Proven efficacy with demonstrated improvements in visceral, hematologic, and certain bone parameters1,4
- Long-term efficacy supported by adult and pediatric data in International Collaborative Gaucher Group (ICGG) Gaucher Registry analyses3,5,a
Established Safety
As the longest-studied ERT1,6
- Adverse reactions reported in adults include back pain, chills, dizziness, fatigue, headache, hypersensitivity reactions, nausea, pyrexia, and vomiting1
- Adverse reactions reported in pediatric patients 2 years of age and older are similar to adults1
- Supported by 10-year data from an international safety monitoring database6
aThe Cerezyme treatment group from the Gaucher Registry analyses represents patients who received either alglucerase or imiglucerase.
Indication
References: 1. Cerezyme (imiglucerase). Prescribing information. Genzyme Corporation, Cambridge, MA. 2. Weinreb N, Taylor J, Cox T, Yee J, vom Dahl S. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Am J Hematol. 2008;83(12):890-895. 3. Weinreb NJ, Camelo JS, Charrow J, et al. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment. Mol Genet Metab. 2021;132(2):100-111. 4. Sims KB, Pastores GM, Weinreb NJ, et al. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet. 2008;73(5):430-440. 5. Andersson H, Kaplan P, Kacena K, Yee J. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics. 2008;122(6):1182-1190. 6. Starzyk K, Richards S, Yee J, Smith SE, Kingma W. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab. 2007;90(2):157-163.
